Zimmer Biomet Holdings (ZBH) Cash from Discontinued Operations (2021 - 2022)

Zimmer Biomet Holdings' (ZBH) quarterly Cash from Discontinued Operations came in at 7000000.0 in Q2 2022, down 79.94% year-on-year from 34900000.0 in Q2 2021, and up 108.92% quarter-over-quarter from 78500000.0 in Q1 2022.

Zimmer Biomet Holdings (ZBH) Cash from Discontinued Operations (2021 - 2022) Analysis & Trends

Zimmer Biomet Holdings' Cash from Discontinued Operations history runs 2 years deep, the most recent figure standing at 7000000.0 for Q2 2022.

  • On a quarterly basis, Cash from Discontinued Operations fell 79.94% year-over-year to 7000000.0 in Q2 2022; TTM through Mar 2023 was 7000000.0, a 206.06% increase from a year earlier, with the FY2022 full-year figure at 71500000.0, down 175.34% from the prior year.
  • Cash from Discontinued Operations rose to 7000000.0 in Q2 2022 per ZBH's latest filing, from 78500000.0 in the prior quarter.
  • Across five years, Cash from Discontinued Operations topped out at 34900000.0 in Q2 2021 and bottomed at 78500000.0 in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Abbott Laboratories 184.10 Bn 176.81 Bn 6.27 Bn -
2 Stryker 128.79 Bn 125.91 Bn 3.81 Bn -
3 Medtronic 108.97 Bn 99.75 Bn 6.41 Bn -
4 Boston Scientific 68.57 Bn 67.12 Bn 3.61 Bn -
5 Edwards Lifesciences 47.64 Bn 43.97 Bn 1.29 Bn -
6 GE HealthCare Technologies 28.40 Bn 26.11 Bn 1.98 Bn -
7 Dexcom 28.32 Bn 27.20 Bn 750.30 Mn -
8 Smith & Nephew 26.94 Bn 26.36 Bn - -
9 Koninklijke Philips 25.45 Bn 22.33 Bn 2.07 Bn -
10 Zimmer Biomet Holdings 18.11 Bn 17.68 Bn 1.51 Bn -

Historic Data

Download Data
DateValue
Jun 30, 2022 7.00 Mn
Jun 30, 2022 7.00 Mn
Mar 31, 2022 -78.50 Mn
Mar 31, 2022 -78.50 Mn
Dec 31, 2021 28.10 Mn
Dec 31, 2021 28.10 Mn
Sep 30, 2021 8.90 Mn
Sep 30, 2021 8.90 Mn
Jun 30, 2021 34.90 Mn
Jun 30, 2021 34.90 Mn
Mar 31, 2021 23.00 Mn
Mar 31, 2021 23.00 Mn